Alumis (NASDAQ:ALMS) Given “Buy” Rating at HC Wainwright

Alumis (NASDAQ:ALMS)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $19.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 289.34% from the company’s current price.

Several other analysts also recently commented on the stock. Oppenheimer started coverage on shares of Alumis in a research report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a report on Thursday, November 14th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $26.57.

Alumis Price Performance

NASDAQ ALMS opened at $4.88 on Monday. Alumis has a 12 month low of $4.36 and a 12 month high of $13.53. The stock’s fifty day moving average price is $6.39 and its 200-day moving average price is $9.12.

Institutional Trading of Alumis

Institutional investors have recently made changes to their positions in the stock. Foresite Capital Management V LLC raised its holdings in shares of Alumis by 3.5% during the fourth quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock valued at $45,426,000 after purchasing an additional 194,459 shares during the last quarter. Foresite Capital Management VI LLC bought a new stake in Alumis in the 4th quarter worth approximately $33,033,000. Samsara BioCapital LLC purchased a new stake in Alumis during the 3rd quarter valued at $34,886,000. Tang Capital Management LLC lifted its holdings in shares of Alumis by 40.6% during the 4th quarter. Tang Capital Management LLC now owns 600,000 shares of the company’s stock valued at $4,716,000 after buying an additional 173,406 shares during the period. Finally, Ally Bridge Group NY LLC boosted its stake in shares of Alumis by 6.4% in the 4th quarter. Ally Bridge Group NY LLC now owns 445,259 shares of the company’s stock worth $3,500,000 after buying an additional 26,843 shares during the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.